ReviewLeukemia2020
Advances in understanding of angioimmunoblastic T-cell lymphoma.
Review in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 162 citations in OpenAlex.
- Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.Leukemia & lymphoma · 2025Trial
- Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma.Frontiers in immunology · 2024Trial
- Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.American journal of hematology · 2022Trial
- Angioimmunoblastic T-cell lymphoma with lymphomatous effusion: Diagnostic challenges and cytology-based approaches.Histology and histopathology · 2026Review
- Single-cell transcriptomic mapping of immune heterogeneity across angioimmunoblastic T-cell lymphoma subtypes.Biomarker research · 2026Article
- B-cell and plasma cell proliferations associated with T follicular helper cell lymphomas: clinical-pathological and genetic features.Virchows Archiv : an international journal of pathology · 2026Article
- Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.British journal of haematology · 2026Article
- Prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma.Infectious agents and cancer · 2026Article
- SenNet Portal: Build, Optimization and Usage.bioRxiv : the preprint server for biology · 2026Article
- Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity.Annals of hematology · 2026Review
- Multiple subcutaneous nodules as the primary presentation of angioimmunoblastic T-cell lymphoma: a case report and literature review.Pathology oncology research : POR · 2026Review
- Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma.American journal of translational research · 2026Article
- The Significance of the Microenvironment in T/Nk-Cell Neoplasms.International journal of molecular sciences · 2025Review
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.Journal of personalized medicine · 2025Review
- Predicting one-year overall survival in patients with AITL using machine learning algorithms: a multicenter study.Scientific reports · 2025Article
- Spatially and Clonally Multiple B-/Plasma Cell Proliferations in T Follicular Helper Cell Lymphoma: A Case Report.Pathology international · 2025Article
- Prognostic value of baseline body composition parameters fromAnnals of hematology · 2025Article
- Integrating genomic and transcriptome features for characterization and prognostic prediction of angioimmunoblastic T-cell lymphoma.Annals of hematology · 2025Article
- Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advances.Clinical and experimental medicine · 2025Review
- A Less Common but Lethal Encounter: Mixed Autoimmune Hemolytic Anemia Unmasking Angioimmunoblastic T-cell Lymphoma.Cureus · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It has been nearly half a century since angioimmunoblastic T-cell lymphoma (AITL) was characterized in the early 1970's. Our understanding of the disease has dramatically changed due to multiple discoveries and insights. One of the key features of AITL is aberrant immune activity. Although AITL is now understood to be a neoplastic disease, pathologists appreciated that it was an inflammatory condition. The more we understand AITL at cellular and genetic levels, the more we view it as both a neoplastic and an inflammatory disease. Here, we review recent progress in our understanding of AITL, focusing on as yet unsolved questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.